EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

NCT04531176 on ClinicalTrials.gov · last registry update 2024-09-19

Stopped early, having planned 74 participants. The sponsor logged completion for 15 August 2022. Primary outcome, as filed: Mean Change in Body Weight Between Baseline and 12 Months. liraglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: The Cleveland Clinic
Sponsor type: Other
Enrollment: 74
Started: 2020-09-01
Primary completion: 2022-08-15 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Change in Body Weight Between Baseline and 12 Months

Conditions studied

Type 2 Diabetes · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.